PF-Atlas › Clinical Trials › NCT01270074

Prevention of Bronchiectasis in Infants With Cystic Fibrosis

Azithromycin · Phase 3

Registry ID
NCT01270074
Phase
Phase 3
Status
Completed
Drug / intervention
Azithromycin
Sponsor
The University of Queensland
Start
2012-04
Enrollment
130
Locations
10

About this trial

The general aim of this project is to conduct a randomized, double-blind, placebo-controlled clinical trial of azithromycin to determine whether treatment from infancy is safe and will prevent the onset of bronchiectasis. One hundred and thirty infants will be recruited from CF clinics in Australia and New Zealand and treated from 3 months to three years of age. The primary outcome will be the proportion with radiologically-defined bronchiectasis at 3 years of age. Safety and mechanistic evaluations will also be undertaken.

View NCT01270074 on ClinicalTrials.gov →

Explore related

All Azithromycin trialsAll IPF trials

Related trials

azithromycin — NCT02173145Azithromycin — NCT05842681Azithromycin — NCT02960503Azithromycin — NCT02003911Azithromycin — NCT02803944
Medical disclaimer. This page summarizes public trial data for NCT01270074 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.